Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.

No abstract is available for this paper.

• Publication year

  1980

• Venue

  Cancer treatment reports

• Publication date

  1980-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 6780190
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer.

  1979cited by this paper
• Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.

  1979cited by this paper
• Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.

  1979cited by this paper
• [Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].

  1978cited by this paper
• Ifosfamide in the treatment of recurrent or disseminated lung cancer A phase II study of two dose schedules

  1978cited by this paper
• Therapy for gastrointestinal cancer with the nitrosoureas alone and in drug combination.

  1976cited by this paper
• Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.

  1976cited by this paper

• Cytotoxic Chemotherapy for Metastatic Renal Cell Cancer

  2008cites this paper
• Chemotherapy for Metastatic Clear-Cell Renal Cell Carcinoma

  2008cites this paper
• Nierenzellkarzinom

  2005cites this paper
• Dosing and side-effects of ifosfamide plus mesna

  2005cites this paper
• Tubular nephrotoxicity during long-term ifosfamide and mesna therapy

  2004cites this paper
• Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment

  2004cites this paper
• Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies

  2004cites this paper
• The role of systemic chemotherapy in the treatment of kidney cancer.

  2003cites this paper
• Chemotherapy for renal cell carcinoma.

  2000cites this paper
• Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.

  1996cites this paper
• Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

  1995cites this paper
• Chemotherapie — Hinweise zur Prophylaxe und Therapie von Komplikationen

  1994cites this paper
• Ifosfamide, mesna, and nephrotoxicity in children.

  1993cites this paper
• Cytotoxic chemotherapy for advanced renal cell carcinoma.

  1993cites this paper
• Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology (SFOP).

  1993cites this paper
• Uroepithelial and nephrotubula toxicity in patients receiving ifosfamide/mesna: Measurement of urinary N-acetyl-β-d-glucosaminidase and β-2-microglobulin

  1992cites this paper
• Uroepithelial and nephrotubular toxicity in patients receiving ifosfamide/mesna: measurement of urinary N-acetyl-beta-D-glucosaminidase and beta-2-microglobulin.

  1992cites this paper
• Encephalopathy in ifosfamide‐treated patients

  1992cites this paper
• Gynecologic Oncology Group studies with ifosfamide.

  1992cites this paper
• Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

  1991cites this paper
• Long-term results in patients with metastatic renal cell carcinoma treated with interferon with or without vinblastine

  1991cites this paper
• Gynecologic Oncology Group experience with ifosfamide.

  1990cites this paper
• Nephrotoxicity after ifosfamide.

  1990cites this paper
• Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.

  1989cites this paper
• Ifosfamide.

  1988cites this paper
• Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma.

  1987cites this paper
• Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.

  1987cites this paper
• Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.

  1987cites this paper
• Advanced Renal Cell Carcinoma: Natural History and Response to Chemotherapy

  1985cites this paper
• Ifosfamide--pharmacology, safety and therapeutic potential.

  1985cites this paper
• Testicular Cancer and Other Tumors of the Genitourinary Tract

  1985cites this paper
• Chemotherapy of advanced renal adenocarcinoma

  1984cites this paper
• Hormonal therapy and chemotherapy of renal-cell carcinoma.

  1983cites this paper
• Treatment of metastatic renal cell carcinoma.

  1983cites this paper
• Phase II study of PALA and AMSA in advanced renal cell carcinoma.

  1983cites this paper
• The anticancer spectrum of ifosfamide.

  1982cites this paper